- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00161642
Study Evaluating CMD-193 in Advanced Malignant Solid Tumors
September 9, 2009 updated by: Wyeth is now a wholly owned subsidiary of Pfizer
A Phase 1 Dose Escalation Study of CMD-193 in Subjects With Advanced Malignant Tumors.
The purpose of this study is to determine the safety, tolerability and maximum tolerated dose of CMD-193.
Preliminary information about how a person's body processes CMD-193 and how CMD-193 affects tumors will also be collected.
Study Overview
Study Type
Interventional
Enrollment (Actual)
54
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19111
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically confirmed malignant solid tumor that has progressed following standard therapy, or for which no standard effective treatment is available
- Tumor expression of Lewis Y antigen ( > or = 20% tumor cells positive for Lewis Y by immunohistochemistry assay)
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria:
- Chemotherapy, radiation therapy, other cancer therapy, or investigational agents within 21 days of the first dose of CMD-193 (42 days if the previous chemotherapy included nitrosoureas or mitomycin C)
- Symptomatic or clinically active CNS metastases. Subjects who have had prior treatment with radiotherapy or surgical resection for CNS metastases will be permitted if CNS metastases have remained stable and have not required any treatment for at least 3 months prior to the first dose of CMD-193.
- Significant prior allergic reaction to recombinant human or murine proteins
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Physical examinations
|
ECG
|
hematology panels
|
Secondary Outcome Measures
Outcome Measure |
---|
Radiographic tumor evaluations
|
blood sampling for pharmacokinetic assessments
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2004
Primary Completion (ACTUAL)
July 1, 2007
Study Completion (ACTUAL)
July 1, 2007
Study Registration Dates
First Submitted
September 7, 2005
First Submitted That Met QC Criteria
September 7, 2005
First Posted (ESTIMATE)
September 12, 2005
Study Record Updates
Last Update Posted (ESTIMATE)
September 10, 2009
Last Update Submitted That Met QC Criteria
September 9, 2009
Last Verified
September 1, 2009
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 3152K1-100
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedUterine Neoplasms | Prostatic Neoplasms | Cervix Neoplasms | Bladder NeoplasmsCanada
-
N.N. Petrov National Medical Research Center of...Active, not recruitingColonic Neoplasms MalignantRussian Federation
-
Peking University First HospitalShengli Oilfield Hospital; The Second Affiliated Hospital of Baotou Medical...Enrolling by invitationRectal Neoplasms MalignantChina
-
Cancer Institute and Hospital, Chinese Academy...CompletedRectal Neoplasms MalignantChina
-
Seattle Children's HospitalSuspendedNeoplasms, Benign | Neoplasms, MalignantUnited States
-
Iuliu Hatieganu University of Medicine and PharmacyInstitutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian...CompletedRetroperitoneal NeoplasmsRomania
-
Pennington Biomedical Research CenterNational Cancer Institute (NCI)RecruitingRectal Neoplasms | Colonic NeoplasmsUnited States
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruitingRadiotherapy | Rectal Neoplasms MalignantChina
Clinical Trials on CMD-193
-
Ludwig Institute for Cancer ResearchWyeth is now a wholly owned subsidiary of PfizerTerminated
-
Wyeth is now a wholly owned subsidiary of PfizerTerminated
-
Second Affiliated Hospital of Soochow UniversityShanghai Regenelead Therapies Co., Ltd.RecruitingAdvanced Parkinson's DiseaseChina
-
Cell Medica LtdTerminatedLymphoma, Extranodal NK-T-Cell | EBVKorea, Republic of, United States, France, United Kingdom
-
University of Texas Southwestern Medical CenterEnrolling by invitationAortic Aneurysm, Abdominal | Thoracic AneurysmUnited States
-
Samsung Medical CenterRecruitingHeart Failure | Microvascular Angina | Non-ischemic CardiomyopathyKorea, Republic of
-
Medstar Health Research InstituteRecruiting
-
University Hospital MuensterNot yet recruitingAortic Aneurysm | Endovascular Aortic Repair | Stent-Graft EndoleakGermany
-
University Hospital MuensterRecruitingAortic Aneurysm | Endovascular Aortic Repair | Stent-Graft EndoleakGermany
-
AmgenRecruitingMTAP-null Non-Small-Cell Lung Cancer | MTAP-null Solid TumorsUnited States, Australia